ABOUT US
We are a Danish biotech aiming to transform the diagnosis of genetic disorders for better disease management.
gMendel® approach
Genotyping
We have developed a proprietary method for high-throughput and cost-effective genotyping. By calculating fractions of reads, our diagnostic tool can identify gene mutations and chromosomal aberrations from a normal karyotype and hence recognize genetic disorders.
AI
We harness the full power of analytics and Artificial Intelligence throughout the complete sequencing process. By using machine learning algorithms, our proprietary technology translates real-time data into accurate and meaningful results.
Diagnosis & Treatment
Our transformative approach bridges the gap between new generation genomic tools and their clinical implementation, providing a shorter path to accurate diagnosis and potential treatment.
10 years horizon
Phase 0: Proof of concept
2020 – Q1 2021
Phase 1: Intelligent diagnosis – gMendel®Test
Q2 2021 – Q2 2023
Our QMS is fully documented, according to international standards. ISO 13485 certification is expected in Q2 2022.
The initial version of our Phivea®Platform is released under the 98/79/EC IVD Directive in Q1 2022.
After registration and approval from the Danish regulatory authorities early 2022, we will continue registration and approval in more EU markets such as Greece, Poland and Spain. Next, we plan to start pilot projects within private/public hospitals and private diagnostic centres in order to collect more data and invaluable customer input for our future products.
We expect to close our first funding round by Q2 2022 and further pursue public grants from the EU.
Next versions of our Phivea®Platform will conform to the 2017/746 IVD regulation.
The gMendel®Test is fully developed.
As from Q4 2022, we will move from SHA hashing and RSA asymmetric key-based algorithms, to blockchain for highest security and patient data encryption.
In parallel, we plan to commercialize a full genome sequencing diagnostic tool, leveraging on the full potential of the Phivea®Platform.
We will continue building interconnected partnerships with industry and communities.
Phase 2: Improving lives of patients and their caregivers – gMendel®Care
Q3 2023 – 2025
Our vision goes beyond technological advancement. With our gMendel®Care initiative, we aim to empower families and their children through social care and equal opportunities, and contribute to building resilient healthcare and welfare systems.
We aim to do this by including the gMendel®Test in national healthcare protocols for prenatal and postnatal diagnosis, creating synergies with pharmaceutical companies to stimulate research and development in orphan drugs, and facilitating collaboration and constructive dialogue with national health policy bodies and platforms.
Phase 3: Intelligent treatment – gMendel®Hope
2026 – 2029
In the future, we hope to combine the gMendel® method with direct methods in protein crystallography.
Our vision is to shape successful treatment protocols on allogeneic bone marrow transplants, by identifying compatible matches to Major Histocompatibility Complex proteins, more accurately and economically.
Meet the team
Chris
Kyriakidis
PhD, MSc, MBA
Co-founder
Kristijan
Jankoski
MSc
Senior Data Scientist
Thomasz
Puk *
MSc, MBA
Head of Q&R
Dariusz
Nabiałczyk *
MSc
Software Architect
Zoran
Velkoski
MSc, MBA
Co-founder
David
Galevski
MSc
Data Scientist
Jarosław
Kowalczyk *
MSc
Quality Assurance Manager
Agnieszka
Tymoszyk *
BSc
QA Engineer
Aleksandar
Nikov
BSc
Head of AI
Anne
Schack
MSc
Genomics Researcher
Dimitris
Kyriakidis
MSc
Advocacy Groups
María del Carmen
Garrido Navas*
PhD, MSc
Clinical Adviser
Gjorgji
Madjarov *
PhD, MSc
AI Advisor
Lukasz
Krych *
PhD, MSc
Genomics Advisor
Maria
Andrielou *
MSc, MA
Head of Marketing & Communication
*Gjorgji: Professor at the Ss Cyril & Methodius University of Skopje
Lukasz: Associate Professor at the University of Copenhagen
Tomasz, Jarosław, Dariusz, Agnieszka: Members of the Star.Global Team
Andrielou: Plankton First S.A., Clean Stories
Carrido Navas: GENyO. Pfizer-University of Granada-Junta de Andalucia Center for Genomics and Oncological Research
Social responsibility
gMendel contributes to the communities where we live. We are committed to our employees, diversity, equity, inclusion, and environmental sustainability.
Purpose matters. It’s the reason we exist, after all. As a purpose-led organisation, we aim to make a positive impact on our people and the society through our core business, as well as initiatives that make our communities a better place to live in.
Impact stories
This is why, in 2020 and 2021, we partnered with Besesaka Foundation, a non-profit organisation in Ghana that is actively changing the lives of children in the local community of Bukom through boxing, education and leadership mindset. Together with Besesaka Foundation and its Boxucation academy, we aimed to nurture talented boys and girls, by providing them complete educational opportunities and the skills they need to succeed in life. After two years of continuous support and engagement, we are now proud to see that this initiative has matured, and activities, now led by the local community, are well on track. Therefore, we believe that it is wiser to channel our efforts into a new inspiring project, still at infancy.
Connect for impact
As we strive to make an even greater impact, we are constantly looking for early-stage inspiring initiatives that promote diversity, equity and inclusion, active at any area, across the globe. If you wish to share and steer the impact of your project with us, please contact us at info@g-mendel.com.